SG Americas Securities
NRIX icon

SG Americas Securities’s Nurix Therapeutics NRIX Stock Holding History

SG Americas Securities’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$841K Buy
34,655
+15,681
+83% +$267K ﹤0.01% 2002
2026
Q1 		$294K Sell
18,974
-11,981
-39% -$199K ﹤0.01% 2464
2025
Q4 		$587K Buy
30,955
+8,993
+41% +$129K ﹤0.01% 2399
2025
Q3 		$203K Buy
+21,962
New +$228K ﹤0.01% 2738
2025
Q2 		– Sell
-21,273
Closed -$253K – 3380
2025
Q1 		$253K Sell
21,273
-8,813
-29% -$147K ﹤0.01% 2357
2024
Q4 		$567K Buy
30,086
+7,141
+31% +$164K ﹤0.01% 1216
2024
Q3 		$516K Sell
22,945
-80,254
-78% -$1.82M ﹤0.01% 1664
2024
Q2 		$2.15M Buy
103,199
+81,005
+365% +$1.26M 0.01% 915
2024
Q1 		$326K Sell
22,194
-4,407
-17% -$47.4K ﹤0.01% 1642
2023
Q4 		$275K Buy
26,601
+5,962
+29% +$40.9K ﹤0.01% 1894
2023
Q3 		$162K Buy
+20,639
New +$188K ﹤0.01% 2442
2023
Q2 		– Sell
-23,725
Closed -$211K – 2888
2023
Q1 		$211K Buy
23,725
+350
+1% +$3.65K ﹤0.01% 2380
2022
Q4 		$257K Sell
23,375
-498
-2% -$6.01K ﹤0.01% 2037
2022
Q3 		$311K Sell
23,873
-10,348
-30% -$164K ﹤0.01% 1960
2022
Q2 		$434K Buy
+34,221
New +$388K ﹤0.01% 2076
2022
Q1 		– Sell
-14,599
Closed -$423K – 3294
2021
Q4 		$423K Sell
14,599
-10,493
-42% -$318K ﹤0.01% 2258
2021
Q3 		$752K Buy
25,092
+16,094
+179% +$497K ﹤0.01% 2153
2021
Q2 		$239K Buy
8,998
+1,504
+20% +$44.2K ﹤0.01% 2262
2021
Q1 		$233K Buy
+7,494
New +$284K ﹤0.01% 2570

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SG Americas Securities's NRIX Position: Q2 2026 in Review

SG Americas Securities increased its Nurix Therapeutics (NRIX) stake by 83% in Q2 2026, buying an estimated $267K and bringing the position to 34,655 shares worth $841K. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

SG Americas Securities first reported a position in NRIX in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.15M in Q2 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • SG Americas Securities held 34,655 shares of Nurix Therapeutics worth $841K as of Q2 2026.
  • SG Americas Securities bought 15,681 Nurix Therapeutics shares in Q2 2026, an estimated $267K.
  • Nurix Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2002 holding.
  • SG Americas Securities first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • SG Americas Securities's Nurix Therapeutics position peaked at $2.15M in Q2 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.